Pancreatic Cancer
Advertisement
Results showed 64% of patients with HRD mPC were progression-free at 6 months with pembrolizumab and olaparib.
A novel KRAS G12D degrader has an acceptable safety profile and positive antitumor activity, especially in pancreatic cancer.
The use of EUS and multimodal AI across all levels of endoscopic expertise proved beneficial.
While germline testing is recommended for patients with PDAC, many do not undergo testing.
A new cohort study sought to determine the effect of selective surveillance on survival in patients at high risk of PDAC.
Dr. Cecchini explains how ctDNA was used in this study as well as which methods were used for analyzing ctDNA levels.
Research has demonstrated that DC-based immunotherapy resulted in T-cell responses against pancreatic cancer antigens.
Patients with PDAC face difficulty achieving durable disease control when following the current standard of care.
Dr. Faber highlights the implications of increased expression of PDCD1LG2, PDCD1, and HAVCR2 in USC PDAC tumors.
The chimeric antigen receptor-modified T-cell therapy CT041 singles out claudin18.2 in solid tumors.
Dr. Knox details the early results of the PASS-01 trial, which looked at PDAC signature stratification for treatment.
The trial compared mFOLFIRINOX vs gemcitabine/nab-paclitaxel in advanced PDAC.
Dr. Weinberg explains the mechanism of action for BXCL701 and how it synergizes with pembrolizumab.
GABARNANCE compared the use of gemcitabine plus nab-paclitaxel with concurrent chemoradiotherapy with S-1.
Tumors analyzed by the researchers were resected or biopsied between 2016 and 2022 at multiple institutions.
PRECEDE offers testing for individuals at high risk of pancreatic cancer, with multiple testing sites located globally.
Dr. Goel discusses how his team's liquid biopsy can be used with CA19-9 to boost the accuracy of detecting pancreatic cancer.
Researchers analyzed the utilization and outcomes of multigene panel GT in patients with PDAC.
Dr. Gulam A. Manji discusses CXCR4 and PD-1 inhibitors and how research has shown a potential benefit of the combination.
Dr. Gulam A. Manji discusses the ARC-8 study on quemliclustat plus gemcitabine/nab-paclitaxel with and without zimberelimab.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.